Two drugs and meningioma risk, and when a side effect is worth mentioning
Original title: Desogestrel, etonogestrel and meningioma risk: how frequent does an adverse effect have to be worth mentioning?
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This looks like a discussion piece, not a new result you can act on.
The short version
This item asks how often a side effect must happen before it is worth mentioning.
What was studied. We only have the title of this item. No summary text was shared, so we cannot say who was studied or what was tested.
What they found. No findings were shared, so we cannot report any. The title points to two drugs, desogestrel and etonogestrel, and the risk of meningioma. It also raises a question about when a side effect is common enough to mention.
What this means, and what it doesn't
What it could mean: There is not enough here to change anything for you today. If you take either drug, ask your own doctor about it.
What it doesn't mean: This does not mean either drug causes meningioma. It also does not mean either drug is safe. No results were shared here, so nothing is proven either way. This is a question raised for discussion, not new advice for your care, and it is not a promise of a cure.
Source: PubMed, August 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.